ESMO videos: Perspectives from ASCO 2018

Watch reports from experts on the key studies presented at ASCO 2018. Learn about practice changing results illustrated by slides from the sessions!

Breast cancer

Joseph Sparano reporting from ASCO 2018, explains that the clinical goal in designing the TAILORx trial was to integrate information from the 21-gene assay in the treatment algorithm, and learn if chemotherapy should be given with adjuvant endocrine therapy in women with HR-positive, HER2-negative, node-negative breast cancer with mid-range Recurrence Score (RS).

Helena Earl reports the results from the PERSEPHONE study that she presented at ASCO 2018 in over 4,000 patients with HER2-positive early breast cancer. It is a non-inferiority trial designed to check if the standard 12 months of adjuvant trastuzumab treatment could be reduced to 6 months with comparable disease-free survival at 4 years.

Genitourinary cancers

Arnaud Mejean reporting from ASCO 2018 explains that the CARMENA trial was designed to learn if nephrectomy is still necessary in metastatic renal cell carcinoma (mRCC)

Lung cancer

Julien Mazières explains that it is a daily challenge for clinicians if to give immunotherapy to patients with oncogene driven non-small cell lung cancer (NSCLC). He reports on the results presented at ASCO 2018 during the symposium dedicated to this question.

Gilberto Lopes reporting from ASCO 2018 explains that the KEYNOTE-042 trial was designed to compare in first-line setting chemotherapy with pembrolizumab in a population of patients with advanced non-small cell lung cancer (NSCLC) whose tumour expressed PDL-1 with a tumour proportion score of at least 1%.

Haematological malignancies

Meletios Dimopoulos reports on the practice changing studies in relapsed and refractory multiple myeloma presented at ASCO 2018.

Meletios Dimopoulos explains that the iNNOVATE trial in Waldenström's macroglobulinemia he presented at ASCO 2018 is a randomised phase III study testing the efficacy and safety of the combination ibrutinib/rituximab against rituximab/placebo.

Gastrointestinal cancers

Thierry Conroy reporting from ASCO 2018 describes the design and key results of the trial that compared adjuvant modified (m) FOLFIRINOX regimen with standard gemcitabine in patients with resected pancreatic cancer.

Elisabeth Smyth reports from ASCO 2018 the results from the KEYNOTE-061 trial that compared pembrolizumab with paclitaxel in patients with gastro-oesophageal carcinoma who progressed after first-line chemotherapy.

Head & neck cancers

Irene Brana reports from ASCO 2018 on results from three combination trials presented in head and neck squamous cell carcinoma (HNSCC).

Translational research and precision medicine

Reporting from ASCO 2018, Mark Ladanyi explains that tumour mutation burden (TMB) is emerging after PD-L1 as a major biomarker of response to immune checkpoints inhibitors. We need to learn more about patients status regarding TMB and PD-L1 across tumour types and two studies addressing this question were presented at this meeting.

Dejan Juric reports on the results presented at ASCO 2018 from studies that tested addition of selective PIK3CA inhibitor in selected populations of patients, but the treatment caused considerable side effects.